Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Glargine and degludec: Solution behaviour of higher dose synthetic insulins.

Adams GG, Alzahrani Q, Jiwani SI, Meal A, Morgan PS, Coffey F, Kok S, Rowe AJ, Harding SE, Chayen N, Gillis RB.

Sci Rep. 2017 Aug 4;7(1):7287. doi: 10.1038/s41598-017-06642-w.

2.

Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience.

Hermansen K, Bohl M, Schioldan AG.

Drugs. 2016 Jan;76(1):41-74. doi: 10.1007/s40265-015-0500-0. Review.

3.

Design and Evaluation of a Robust PID Controller for a Fully Implantable Artificial Pancreas.

Huyett LM, Dassau E, Zisser HC, Doyle FJ 3rd.

Ind Eng Chem Res. 2015 Oct 28;54(42):10311-10321. Epub 2015 Jun 9.

4.

Two Cases of Allergy to Insulin in Gestational Diabetes.

Kim GJ, Kim SB, Jo SI, Shin JK, Kwon HS, Jeong H, Son JW, Lee SS, Kim SR, Kim BK, Yoo SJ.

Endocrinol Metab (Seoul). 2015 Sep;30(3):402-7. doi: 10.3803/EnM.2015.30.3.402. Epub 2015 May 18.

5.

Towards a Physiological Prandial Insulin Profile: Enhancement of Subcutaneously Injected Prandial Insulin Using Local Warming Devices.

El-Laboudi AH, Oliver N.

Diabetes Ther. 2015 Sep;6(3):257-72. doi: 10.1007/s13300-015-0125-z. Epub 2015 Sep 2.

6.

Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?

Home PD.

Diabetes Obes Metab. 2015 Nov;17(11):1011-20. doi: 10.1111/dom.12501. Epub 2015 Sep 23. Review.

7.

Rapid model exploration for complex hierarchical data: application to pharmacokinetics of insulin aspart.

Goudie RJ, Hovorka R, Murphy HR, Lunn D.

Stat Med. 2015 Oct 15;34(23):3144-58. doi: 10.1002/sim.6536. Epub 2015 May 26.

9.

Cumulative clinical experience with use of insulin lispro: critical appraisal, role in therapy, and patient considerations.

Uy J, Fogelfeld L, Guerra Y.

Diabetes Metab Syndr Obes. 2012;5:1-10. doi: 10.2147/DMSO.S15404. Epub 2012 Jan 10.

10.

Closed-loop insulin delivery utilizing pole placement to compensate for delays in subcutaneous insulin delivery.

Loutseiko M, Voskanyan G, Keenan DB, Steil GM.

J Diabetes Sci Technol. 2011 Nov 1;5(6):1342-51.

11.

Non-equivalent role of inter- and intramolecular hydrogen bonds in the insulin dimer interface.

Antolíková E, Žáková L, Turkenburg JP, Watson CJ, Hančlová I, Šanda M, Cooper A, Kraus T, Brzozowski AM, Jiráček J.

J Biol Chem. 2011 Oct 21;286(42):36968-77. doi: 10.1074/jbc.M111.265249. Epub 2011 Aug 31.

12.

MATHEMATICAL MODELS OF SUBCUTANEOUS INJECTION OF INSULIN ANALOGUES: A MINI-REVIEW.

Li J, Johnson JD.

Discrete Continuous Dyn Syst Ser B. 2009 Sep;12(2):401-414.

13.

Insulin glulisine in the management of diabetes.

Yamada S.

Diabetes Metab Syndr Obes. 2009 Jul 7;2:111-5.

14.

Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study.

Gagnon-Auger M, du Souich P, Baillargeon JP, Martin E, Brassard P, Ménard J, Ardilouze JL.

Diabetes Care. 2010 Dec;33(12):2502-7. doi: 10.2337/dc10-1126. Epub 2010 Sep 14.

15.

Update on mathematical modeling research to support the development of automated insulin delivery systems.

Steil GM, Hipszer B, Reifman J.

J Diabetes Sci Technol. 2010 May 1;4(3):759-69.

16.

Establishing a continuous glucose monitoring program.

Wolpert H.

J Diabetes Sci Technol. 2008 Mar;2(2):307-10.

18.

Supplemental Content

Support Center